RAPGEF4 and nasopharyngeal carcinoma: To evaluate the influence of EPAC2 on therapeutic outcomes after NPC transplantation at the sub-acute stage after SCI, we administered a specific EPAC2 inhibitor (ESI-05) alongside NPC transplantation (schema shown in Fig. 5A).